Hematology – Clinical Fellowships

The University of Calgary offers a variety of fellowship programs in malignant hematology, including lymphoma, plasma cell dyscrasias, myeloid malignancies, and hematopoietic stem cell transplantation. These fellowships are generally 1-2 years in duration, and include both clinical and research experience in the management of these malignancies. The clinical and research experience is flexible and intended to meet the educational and career goals of the applicant. For more information about a specific program, and the application procedure, please contact jeanne.sheldon@ahs.ca.

Lymphoma

Current Program Director: Dr. Lesley Street (lesley.street@ahs.ca)
This one year fellowship focuses on the treatment of patients with lymphoma and chronic lymphocytic leukemia. This includes a strong clinical program, with approximately 250 new patients with lymphoid malignancies seen at the Tom Baker Cancer Centre annually, as well as an active hematopoietic stem cell transplantation program (autologous and allogeneic) for lymphoid malignancies. Fellows are also provided the opportunity to conduct research projects as an important part of this fellowship training.

Plasma Cell Disorders

This one to two year fellowship focuses on the treatment of patients with plasma cell disorders including multiple myeloma and amyloidosis. This includes a strong clinical and research program, as well as an active autologous hematopoietic stem cell transplantation program. Fellows are encouraged to conduct research projects as an important part of this fellowship training.

Hematopoeitic Stem Cell Transplant

Current Program Director: Dr. Lynn Savoie (lynn.savoie@ahs.ca)
The Alberta Blood and Marrow Transplant Program (ABMTP) at the University of Calgary offers a one to two-year clinical fellowship program that provides specialized training for physicians interested in hematopoietic stem cell transplantation. The ABMTP acts as a referral centre for all allogeneic transplants in the province, and all pediatric transplants and autologous transplants for Southern Alberta. Over the past 30 years, it has become one of Canada’s largest BMT programs, treating over 150 adult patients in Calgary each year. Within Canada it performs substantially more unrelated transplants, including cord blood transplantation, than any other adult program, and is the only combined adult and pediatric program. Our program has a solid international reputation as an academically productive and innovative group. It is very active in research, including prospective multicentre cooperative group studies, industry sponsored clinical trials, local investigator-initiated studies, retrospective studies, as well as translational research projects. Several division members have national and international research reputations, including Dr. Andrew Daly for clinical research in all areas of allogeneic HSCT, Dr. Doug Stewart for clinical research in the area of lymphoma, Dr. Nizar Bahlis for clinical and translational research in the area of multiple myeloma, and Dr. Jan Storek who is evaluating immunological aspects of HSCT including immune recovery and infectious complications.

Hemostasis Fellowship Program

Current Program Director: Dr. Man Chiu Poon (mcpoon@ucalgary.ca)
A formal fellowship training program has been offered through the Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program since 2007. The program specializes in: congenital and acquired bleeding disorders, hemoglobinopathies, hereditary angioedema and paroxysmal nocturnal hemoglobinuria (PNH) as well as transfusion dependent congenital bone marrow failure syndromes. The multidisplinary team provides comprehensive management to improve outcomes and patient/family quality of life through patient-centered evidence-based clinical care, education and research. Fellows will have active clinical involvement in this program and are encouraged to conduct clinical investigations to further our knowledge on the pathogenic mechanisms, diagnosis and management of these rare blood and bleeding disorders.